Beone Medicines (ONC) Fundamental Analysis: Revenue, Earnings & Valuation

1.92 / 10

Underperform

Fundamental analysis rates the stock as Underperform with a 1.9/10 quality score. Inventory turnover and ROA are modestly positive, yet asset‑market value disparity and PB‑ROE gaps raise risk, leading to an overall weak financial profile.

Analysis Checks(8/10)

ROA (%)

Value4.07

Score2/3

Weight6.17%

1M Return0.82%

Total operating revenue (YoY growth rate %)

Value40.23

Score2/3

Weight1.64%

1M Return0.26%

Inventory turnover ratio

Value1.21

Score2/3

Weight-8.83%

1M Return-1.27%

PB-ROE

Value2.94

Score1/3

Weight12.10%

1M Return1.61%

Rate of return on total assets (%)

Value5.73

Score3/3

Weight10.18%

1M Return1.35%

Income tax / Total profit (%)

Value31.17

Score2/3

Weight32.66%

1M Return4.29%

Annualized net profit margin on total assets (%)

Value4.07

Score2/3

Weight6.17%

1M Return0.82%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.01

Score2/3

Weight-7.16%

1M Return-1.15%

Cost of sales ratio (%)

Value12.51

Score3/3

Weight5.08%

1M Return0.69%

Asset-MV

Value-0.55

Score1/3

Weight41.99%

1M Return5.61%

Is ONC undervalued or overvalued?

ONC scores 1.92/10 on fundamentals and holds a Premium valuation at present. Backed by its 7.46% ROE, 5.37% net margin, 109.99 P/E ratio, 7.24 P/B ratio, and 142.55% earnings growth, these metrics solidify its Underperform investment rating.